Advertisement

Topics

SanBio Group Company Profile

06:18 EDT 20th April 2019 | BioPortfolio

SanBio is a regenerative medicine company headquartered in Tokyo and Mountain View, California, with cell-based products in various stages of research, development and clinical trials. Its proprietary cell-based investigational product, SB623, is currently in a Phase 2b clinical trial for treatment of chronic motor deficit resulting from ischemic stroke, and in a Phase 2 clinical trial for treatment of chronic motor deficit resulting from traumatic brain injury. More information about SanBio, Inc. is available at http://sanbio.com.


News Articles [728 Associated News Articles listed on BioPortfolio]

SanBio reports positive results from Phase II SB623 trial

SanBio Group has reported positive results from the Phase II STEMTRA trial after it met the primary endpoint. The STEMTRA...Read More... The post SanBio reports positive results from Phase II SB623 tr...

SanBio Announces Phase 2 STEMTRA Trial Using SB623 Cells for Treatment of Patients with Traumatic Brain Injury Met Primary Endpoint

The SanBio Group (SanBio Co., Ltd. and subsidiary SanBio Inc.; together, the “Company”) announces today that the Phase 2 STEMTRA trial using SB623 cells for the treatment of p...

Notice of Personnel Changes to Corporate Officers at SanBio Co., Ltd. and at US Subsidiary SanBio, Inc.

SanBio Co., Ltd. and US subsidiary SanBio, Inc. conducted the following personnel transfers, effective October 1, 2018. 1. Transfer DetailsAkihiro Tsujimura will become a...

SanBio to Announce the Results of a Phase 2 STEMTRA Trial Regarding the Use of Regenerative Cell Medicine SB623 as a Treatment for TBI at an Annual Scientific Meeting of the American Association of Neurological Surgeons

The SanBio Group (SanBio Co., Ltd. and SanBio, Inc.) (TOKYO: 4592), a scientific leader in regenerative medicine for neurological disorders, today announced its plan to make publi...

SanBio Announces SB623 Regenerative Cell Therapy for Traumatic Brain Injury Has Received Ministry of Health, Labour and Welfare (MHLW) Sakigake Designation

The SanBio Group (SanBio Co., Ltd. and SanBio, Inc.) (TOKYO:4592), a scientific leader in regenerative medicine for neurological disorders, announced today that SB623, a regenerat...

SanBio: Addition of a Cerebral Hemorrhage Program for SB623 Regenerative Cell Medicine

At a meeting held today, the Board of Directors of SanBio Co., Ltd. (hereinafter, the “Company”) resolved to add a program for treatment of chronic motor deficit from cerebral...

SanBio’s SB623 meets in Phase II for TBI

If you want to see a $4bn stem cell scam going down to earth today watch Sanbio. After a massive pump on Tokyo exchange driven by retail on “positive” headline data in TBI, it’s announced this morning its Phase IIb trial with SB623 in stroke has fai

If you want to see a $4bn stem cell scam going down to earth today watch Sanbio. After a massive pump on Tokyo exchange driven by retail on “positive” headline data in TBI, it’s anno...

Drugs and Medications [0 Results]

None

PubMed Articles [1674 Associated PubMed Articles listed on BioPortfolio]

Isolation and exploitation of minority: Game theoretical analysis.

We investigate various group-size distributions occurring in a situation where each group's resource is exposed to appropriation by other groups. The amount of appropriation depends on the size differ...

Characteristics of 2017 GOLD COPD group A: a multicenter cross-sectional CAP study in Japan.

The 2017 GOLD ABCD classification shifts patients from groups C-D to A-B. Group A was the most widely distributed group in several studies. It would be useful to understand the characteristics for gro...

Appearance of large scavenger receptor A-positive cells in peripheral blood: A potential risk factor for severe exacerbation of chronic obstructive pulmonary disease.

Fresh peripheral blood (PB) samples from 432 outpatients with stable chronic obstructive pulmonary disease (COPD) were examined. Patients were classified into Group A (large SRA cells were undetected)...

Comparison of Congenital Malformations among Babies Born after Administration of Letrozole or Clomiphene Citrate for Infertility Treatment in a Korean Cohort.

This retrospective study investigated and compared the incidence of congenital foetal anomalies after letrozole versus clomiphene citrate (CC) administration for infertility treatment. Data from 142 n...

The apoptotic effects of bisphenol A exposure on the rat ovary: an experimental study.

Bisphenol A (BPA) is a key endocrine-disrupting chemical (EDC) in the manufacturing industry. It is found in the structure of compounds such as polycarbonate and epoxy in combination with other chemic...

Clinical Trials [4430 Associated Clinical Trials listed on BioPortfolio]

MAC-cbt Group Therapy for Adults With ADHD

The study is developed to validate a new short psychotherapeutic group treatment for adults with ADHD diagnosis. The participants will be treated in a monocentric, parallel group randomize...

The Influence of Hypotensive Drugs on Mineral Status in Experimental and Clinical Studies

The aim of the study was to evaluate the effects of hypotensive treatment combined with a higher zinc supply in the diet and supplements on the mineral status and selected biochemical para...

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants

The purpose of this study is to evaluate the safety and tolerability of single oral doses of TAK-828 in healthy non-Japanese and Japanese participants.

Ultrasound and Exercises in Knee Osteoarthritis

The aim of this investigation is to compare the effects of continuous (CUS) and pulsed (PUS) ultrasound associated with a program of exercises on pain, range of motion, muscle strength, fu...

Technical Development of Multi-Parametric Renocerebral MRI

The purpose of the study is to investigate the associations of the age-related changes in the brain, kidneys and cognitive performance in healthy adults by utilizing multiple anatomic and ...

Companies [1667 Associated Companies listed on BioPortfolio]

SanBio Group

SanBio is a regenerative medicine company headquartered in Tokyo and Mountain View, California, with cell-based products in various stages of research, development and clinical tr...

SanBio, Inc.

SanBio is a regenerative medicine company with cell based products in various stages of research, development and clinical trials. Its proprietary cell based product, SB623, is be...

SanBio Co., Ltd.

SanBio (TOKYO:4592) is a leading regenerative medical products company headquartered in Tokyo and Mountain View, California, with cell-based products in various stages of research...

SANBIO BV

Through regular contact with our customers in the Benelux and Germany, Sanbio has been able to offer a wide range of biotechnology and research products in the field of immunology, pathology, molecula...

SanBio, Co. Ltd.

More Information about "SanBio Group" on BioPortfolio

We have published hundreds of SanBio Group news stories on BioPortfolio along with dozens of SanBio Group Clinical Trials and PubMed Articles about SanBio Group for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of SanBio Group Companies in our database. You can also find out about relevant SanBio Group Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...


Corporate Database Quicklinks



Searches Linking to this Company Record